Fineline Cube

Follow:
14409 Articles
Guangzhou Innogen Pharmaceutical Files for IPO on Hong Kong Stock Exchange
CompanyDeals

Guangzhou Innogen Pharmaceutical Files for IPO on Hong Kong Stock Exchange

Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals in Asset Purchase Deal
CompanyDeals

Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals in Asset Purchase Deal

GSK plc Enters Exclusive Option Agreement with Duality Biologics for ADC Candidate DB-1324
CompanyDeals

GSK plc Enters Exclusive Option Agreement with Duality Biologics for ADC Candidate DB-1324

Keros Therapeutics and Takeda Enter Licensing Agreement for Elritercept Development
CompanyDeals

Keros Therapeutics and Takeda Enter Licensing Agreement for Elritercept Development

Gilead Sciences Secures Exclusive Option for Tubulis' Tubutecan and Alco5 Platforms to Develop ADC
CompanyDeals

Gilead Sciences Secures Exclusive Option for Tubulis’ Tubutecan and Alco5 Platforms to Develop ADC

Ophthalmology Biotech Cloudbreak Pharma Inc. Pursues Hong Kong IPO
CompanyDeals

Ophthalmology Biotech Cloudbreak Pharma Inc. Pursues Hong Kong IPO

COUR Pharmaceutical Enters Licensing Agreement with Genentech for Autoimmune Disease Treatment
CompanyDeals

COUR Pharmaceutical Enters Licensing Agreement with Genentech for Autoimmune Disease Treatment

Guangzhou Virotech's Oncolytic Virus M1 Receives Tacit Clinical Approval from NMPA
CompanyDrug

Guangzhou Virotech’s Oncolytic Virus M1 Receives Tacit Clinical Approval from NMPA

Ipsen Secures Global Licensing Agreement for Biomunex Pharmaceuticals' BMX-502 T Cell Engager
CompanyDeals

Ipsen Secures Global Licensing Agreement for Biomunex Pharmaceuticals’ BMX-502 T Cell Engager

OncoC4, Inc. Receives FDA Clearance for AI-081, a PD-1 and VEGF Bispecific Antibody
CompanyDrug

OncoC4, Inc. Receives FDA Clearance for AI-081, a PD-1 and VEGF Bispecific Antibody

Luye Pharma's Zepzelca Receives NMPA Approval for Metastatic Small Cell Lung Cancer Treatment
CompanyDrug

Luye Pharma’s Zepzelca Receives NMPA Approval for Metastatic Small Cell Lung Cancer Treatment

Sacituzumab Tirumotecan Earns FDA Breakthrough Therapy Designation for EGFR Mutated NSCLC
CompanyDrug

Sacituzumab Tirumotecan Earns FDA Breakthrough Therapy Designation for EGFR Mutated NSCLC